Clinical trial
A Study of SEA-CD40 Given With Other Drugs in Cancers
NCT04993677
Study timeline
Study start (actual)2021-10-06Date precision: day
Registry last updated2025-05-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Carcinoma, Non-Small- Cell Lungunresolved
Interventions
SEA-CD40DRUG
pemetrexedDRUG · verified · RxNorm: pemetrexed
carboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Seagen Inc.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
San FranciscoCalifornia, United States2MinneapolisMinnesota, United States2HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1NashvilleTennessee, United States1ClevelandOhio, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1IndianapolisIndiana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04993677 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.